AmerisourceBergen (NYSE:ABC) issued its quarterly earnings data on Thursday. The company reported $1.61 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.58 by $0.03, Briefing.com reports. AmerisourceBergen had a return on equity of 47.88% and a net margin of 0.54%. The company had revenue of $45.64 billion during the quarter, compared to the consensus estimate of $45.15 billion. During the same period last year, the company earned $1.45 earnings per share. The firm’s revenue was up 5.4% compared to the same quarter last year. AmerisourceBergen updated its FY20 guidance to $7.30-7.60 EPS.
NYSE ABC traded up $1.99 during trading hours on Friday, hitting $86.07. 976,127 shares of the company’s stock were exchanged, compared to its average volume of 1,377,801. The stock has a 50-day simple moving average of $84.48 and a 200 day simple moving average of $83.73. AmerisourceBergen has a 1-year low of $69.36 and a 1-year high of $94.75. The firm has a market cap of $18.10 billion, a price-to-earnings ratio of 13.26, a PEG ratio of 1.44 and a beta of 0.98. The company has a current ratio of 0.95, a quick ratio of 0.56 and a debt-to-equity ratio of 1.40.
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Monday, November 18th will be paid a dividend of $0.40 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $1.60 annualized dividend and a yield of 1.86%. AmerisourceBergen’s dividend payout ratio is currently 24.65%.
A number of equities analysts have recently issued reports on the company. ValuEngine downgraded AmerisourceBergen from a “hold” rating to a “sell” rating in a research report on Friday, November 1st. JPMorgan Chase & Co. lowered their price objective on AmerisourceBergen from $95.00 to $91.00 and set a “neutral” rating for the company in a research report on Friday. Deutsche Bank assumed coverage on AmerisourceBergen in a research report on Thursday, September 12th. They set a “hold” rating and a $91.00 price objective for the company. Morgan Stanley lowered their price objective on AmerisourceBergen from $91.00 to $83.00 and set an “equal weight” rating for the company in a research report on Friday, September 6th. Finally, TheStreet cut AmerisourceBergen from a “b” rating to a “c+” rating in a research note on Thursday. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $87.78.
AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers.
Receive News & Ratings for AmerisourceBergen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmerisourceBergen and related companies with MarketBeat.com's FREE daily email newsletter.